HomePHIO • NASDAQ
Phio Pharmaceuticals Corp
add
$1.03
5.50%
Pre-market:(3.88%)+0.040
$1.07
Closed: Apr 8, 8:10:04 AM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 4.33M | 529.65% |
Net income | -1.63M | 14.20% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -1.67M | 0.65% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 5.38M | -36.61% |
Total assets | 5.74M | -38.72% |
Total liabilities | 1.02M | -37.88% |
Total equity | 4.72M | — |
Shares outstanding | 4.78M | — |
Price to book | 0.40 | — |
Return on assets | -72.14% | — |
Return on capital | -86.57% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -1.63M | 14.20% |
Cash from operations | -1.37M | 42.15% |
Cash from investing | 8.00K | — |
Cash from financing | 1.36M | -43.61% |
Net change in cash | -8.00K | -124.24% |
Free cash flow | -930.25K | 40.95% |
Previous close
$1.09
Day range
$1.00 - $1.10
Year range
$1.00 - $9.79
Market cap
4.92M USD
Avg Volume
111.74K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Founded
2011
Headquarters
Website
Employees
5
